Mechanisms and drug therapy of pulmonary hypertension at high altitude

High Altitude Medicine and Biology

Volumn 14, Issue 2, 2013, Pages 126-133

  Scherrer, Urs ^a,b   Allemann, Yves ^a   Rexhaj, Emrush ^a   Rimoldi, Stefano F ^a   Sartori, Claudio ^c  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSIDAD DE TARAPACÁ   (Chile)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Chronic mountain sickness; Fetal growth; Free radicals; High altitude pulmonary edema

Indexed keywords

ACETAZOLAMIDE; CYCLIC GMP; DEXAMETHASONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; HYPOXIA INDUCIBLE FACTOR; NIFEDIPINE; NITRIC OXIDE; PHENTOLAMINE;

ADRENERGIC SYSTEM; ALTITUDE ACCLIMATIZATION; ALTITUDE DISEASE; ARTICLE; CAUCASIAN; DOWN SYNDROME; FETUS HYPOXIA; HEART RIGHT LEFT SHUNT; HUMAN; HYPOXEMIA; HYPOXIA; HYPOXIC LUNG VASOCONSTRICTION; INFERTILITY THERAPY; LUNG ARTERY PRESSURE; LUNG EDEMA; METABOLIC DISORDER; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATENT FORAMEN OVALE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RACE DIFFERENCE; RESPIRATORY EPITHELIUM; TRISOMY 21; VENOUS OXYGEN TENSION;

ACUTE DISEASE; ADAPTATION, PHYSIOLOGICAL; ALTITUDE SICKNESS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; ENDOTHELIN-1; FEMALE; FETAL DEVELOPMENT; FORAMEN OVALE, PATENT; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; OXIDATIVE STRESS; PRE-ECLAMPSIA; PREGNANCY; PULMONARY EDEMA; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 84879611711     PISSN: 15270297     EISSN: 15578682     Source Type: Journal    
DOI: 10.1089/ham.2013.1006     Document Type: Article

References (77)

1. Ahsan A, Charu R, Pasha MA, Norboo T, Afrin F, and Baig MA. (2004). eNOS allelic variants at the same locus associate with HAPE and adaptation. Thorax 59:1000-1002 (Pubitemid 39490790)
2. Allemann Y, Hutter D, Lipp E, et al. (2006). Patent foramen ovale and high-Altitude pulmonary edema. JAMA 296:2954-2958 (Pubitemid 46021499)
3. Allemann Y, Stuber T, de Marchi SF, et al. (2012). Pulmonary artery pressure and cardiac function in children and adolescents after rapid ascent to 3450 m. Am J Physiol 302:H2646-2653
4. Antoniu SA. (2012). Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. Expert opinion on therapeutic targets. 16:355-363
5. Bailey DM, Dehnert C, Luks AM, et al. (2010). High-Altitude pulmonary hypertension is associated with a free radicalmediated reduction in pulmonary nitric oxide bioavailability. J Physiol 588:4837-4847
6. Bailey DM, Rimoldi SF, Rexhaj E, et al. (2013). Oxidativenitrosative stress and systemic vascular function in highlanders with and without exaggerated hypoxemia. Chest 142:444-451
7. Barker DJ. (1999). Fetal origins of cardiovascular disease. Ann Med 31:3-6 (Pubitemid 29209697)
8. Beall CM, Laskowski D, Strohl KP, et al. (2001). Pulmonary nitric oxide in mountain dwellers. Nature 414:411-412 (Pubitemid 34173716)
9. Benumof JL, Pirlo AF, Johanson I, and Trousdale FR. (1981). Interaction of PVO2 with PAO2 on hypoxic pulmonary vasoconstriction. J Appl Physiol 51:871-874
10. Blitzer ML, Loh E, Roddy MA, Stamler JS, and Creager MA. (1996). Endothelium-Derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J Am Coll Cardiol 28:591-596 (Pubitemid 26288638)
11. Bras A, Monteiro C, and Rueff J. (1989). Oxidative stress in trisomy 21. A possible role in cataractogenesis. Ophthalmic Paediatr Genet 10:271-277 (Pubitemid 20049382)
12. Brennan LA, Steinhorn RH, Wedgwood S, et al. (2003). Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: A role for NADPH oxidase. Circ Res 92:683-691 (Pubitemid 36417704)
13. Busch T, Bartsch P, Pappert D, et al. (2001). Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-Altitude pulmonary edema. Am J Respir Crit Care Med 163:368-373 (Pubitemid 32158514)
14. Carratelli M, Porcaro L, Ruscica M, De Simone E, Bertelli AA, and Corsi MM. (2001). Reactive oxygen metabolites and prooxidant status in children with Down's syndrome. Int J Clin Pharmacol Res 21:79-84 (Pubitemid 34074274)
15. Champion HC, Bivalacqua TJ, Greenberg SS, Giles TD, Hyman AL, and Kadowitz PJ. (2002). Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-Deficient mice. Proc Natl Acad Sci USA 99:13248-13253
16. Chen HI. (1995). Hemodynamic mechanisms of neurogenic pulmonary edema. Biol Signals 4:186-192 (Pubitemid 26008691)
17. Cook S, Vollenweider P, Menard B, Egli M, Nicod P, and Scherrer U. (2003). Increased eNO and pulmonary iNOS expression in eNOS null mice. Eur Respir J 21:770-773 (Pubitemid 36592282)
18. de Haan JB, Susil B, Pritchard M, and Kola I. (2003). An altered antioxidant balance occurs in Down syndrome fetal organs: Implications for the ''gene dosage effect'' hypothesis. J Neural Transm Suppl 67:67-83 (Pubitemid 38339923)
19. Droma Y, Hanaoka M, Basnyat B, et al. (2006). Genetic contribution of the endothelial nitric oxide synthase gene to high altitude adaptation in sherpas. High Alt Med Biol 7:209-220 (Pubitemid 46157307)
20. Droma Y, Hanaoka M, Ota M, et al. (2002). Positive association of the endothelial nitric oxide synthase gene polymorphisms with high-Altitude pulmonary edema. Circulation 106:826-830
21. Duplain H, Peterson KL, Lepori M, et al. (1999). Augmented hypoxic pulmonary vasoconstriction and increased susceptibility to lung edema in heterozygous endothelial nitric oxide synthase (eNOS) deficient mice. Am J Respir Crit Care Med 1999;suppl.153
22. Duplain H, Sartori C, Lepori M, et al. (2000). Exhaled nitric oxide in high-Altitude pulmonary edema: Role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am J Respir Crit Care Med 162:221-224 (Pubitemid 30469824)
23. Duplain H, Vollenweider L, Delabays A, Nicod P, Bärtsch P, and Scherrer U. (1999). Augmented sympathetic activation during short-Term hypoxia and high-Altitude exposure in subjects susceptible to high altitude pulmonary edema. Circulation 99:1713-1718 (Pubitemid 29162484)
24. Durmowicz AG. (2001). Pulmonary edema in 6 children with Down syndrome during travel to moderate altitudes. Pediatrics 108:443-447
25. Faoro V, Boldingh S, Moreels M, et al. (2009). Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. Chest 135:1215-1222
26. Hackett PH, Roach RC, Hartig GS, Greene ER, and Levine BD. (1992). The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: A comparison. Int J Sports Med 13:S68-71
27. Hackett PH, Roach RC, Schoene RB, Harrison GL, and Mills WJ. (1988). Abnormal control of ventilation in high-Altitude pulmonary edema. J Appl Physiol 64:1268-1272 (Pubitemid 18088552)
28. Hakim TS, and Mortola JP. (1990). Pulmonary vascular resistance in adult rats exposed to hypoxia in the neonatal period. Can J Physiol Pharmacol 68:419-424 (Pubitemid 20130608)
29. Hansen J, and Sander M. (2003). Sympathetic neural overactivity in healthy humans after prolonged exposure to hypobaric hypoxia. J Physiol 546:921-929 (Pubitemid 36204524)
30. Hoit BD, Dalton ND, Erzurum SC, Laskowski D, Strohl KP, and Beall CM. (2005). Nitric oxide and cardiopulmonary hemodynamics in Tibetan highlanders. J Appl Physiol 99:1796-1801 (Pubitemid 41547177)
31. Hoshikawa Y, Ono S, Suzuki S, et al. (2001). Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 90:1299-1306 (Pubitemid 32220912)
32. Iannello RC, Crack PJ, de Haan JB, and Kola I. (1999). Oxidative stress and neural dysfunction in Down syndrome. J Neural Transm Suppl 57:257-267
33. Jayet PY, Rimoldi SF, Stuber T, et al. (2010). Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia. Circulation 122:488-494
34. Joanny P, Steinberg J, Robach P, et al. (2001). Operation Everest III (Comex'97): The effect of simulated sever hypobaric hypoxia on lipid peroxidation and antioxidant defence systems in human blood at rest and after maximal exercise. Resuscitation 49:307-314 (Pubitemid 32588709)
35. Kerut EK, Norfleet WT, Plotnick GD, and Giles TD. (2001). Patent foramen ovale: A review of associated conditions and the impact of physiological size. J Am Coll Cardiol 38:613-623 (Pubitemid 32835725)
36. Kojonazarov B, Isakova J, Imanov B, et al. (2012). Bosentan reduces pulmonary artery pressure in high altitude residents. High Alt Med Biol 13:217-223
37. Kojonazarov B, Myrzaakhmatova A, Sooronbaev T, Ishizaki T, and Aldashev A. (2012). Effects of fasudil in patients with high-Altitude pulmonary hypertension. Eur Respir J 39:496-498
38. Kourembanas S, Marsden PA, McQuillan RP, and Faller DV. (1991). Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 88:1054-1057
39. Krasney JA. (1994). A neurogenic basis for acute altitude illness. Med Sci Sports Exerc 26:195-208 (Pubitemid 24054781)
40. Leon-Velarde F, Villafuerte FC, and Richalet JP. (2010). Chronic mountain sickness and the heart. Prog Cardiovasc Dis 52:540-549
41. Levine BD, Grayburn PA, Voyles WF, Greene ER, Roach RC, and Hackett PH. (1991). Intracardiac shunting across a patent foramen ovale may exacerbate hypoxemia in high-Altitude pulmonary edema. Ann Intern Med 114:569-570
42. Luks AM, McIntosh SE, Grissom CK, et al. (2010). Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med 21:146-155
43. Maggiorini M. Prevention and treatment of high-Altitude pulmonary edema. (2010). Prog Cardiovasc Dis 52:500-506
44. Maggiorini M, Brunner-La Rocca HP, Peth S, et al. (2006). Both tadalafil and dexamethasone may reduce the incidence of high-Altitude pulmonary edema: A randomized trial. Ann Intern Med 145:497-506 (Pubitemid 46780953)
45. Maggiorini M, Melot C, Pierre S, et al. (2001). High-Altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 103:2078-2083 (Pubitemid 32373011)
46. Modesti PA, Vanni S, Morabito M, et al. (2006). Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. Circulation 114:1410-1416 (Pubitemid 44454561)
47. Monge C. Life in the Andes and chronic mountain sickness. (1942). Science 95:79-84
48. Oelz O, Maggiorini M, Ritter M, et al. (1992). Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. Int J Sports Med 13:S65-68
49. Owlya R, Vollenweider L, Trueb L, et al. (1997). Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during exercise in humans. Circulation 1997;96:3897-3903
50. Penaloza D, and Arias-Stella J. (2007). The heart and pulmonary circulation at high altitudes: Healthy highlanders and chronic mountain sickness. Circulation 115:1132-1146 (Pubitemid 46673174)
51. Pham I, Wuerzner G, Richalet JP, Peyrard S, and Azizi M. (2012). Bosentan effects in hypoxic pulmonary vasoconstriction: Preliminary study in subjects with or without high altitude pulmonary edema-history. Pulm Circ 2:28-33
52. Pratali L, Rimoldi SF, Rexhaj E, et al. (2012). Exercise induces rapid interstitial lung water accumulation in patients with chronic mountain sickness. Chest 141:953-958
53. Randin D, Vollenweider P, Tappy L, Jéquier E, Nicod P, and Scherrer U. (1995). Suppression of alcohol-induced hypertension by dexamethasone. N Engl J Med 332:1733-1737
54. Rexhaj E, Bloch J, Jayet PY, et al. (2011). Fetal programming of pulmonary vascular dysfunction in mice: Role of epigenetic mechanisms. Am J Physiol 301:H247-252
55. Richalet JP, Rivera-Ch M, Maignan M, et al. (2008). Acetazolamide for Monge's disease: Efficiency and tolerance of 6-month treatment. Am J Respir Crit Care Med 177:1370-1376 (Pubitemid 351860915)
56. Rimoldi SF, Sartori C, Seiler C, et al. (2010). High-Altitude exposure in patients with cardiovascular disease: Risk assessment and practical recommendations. Prog Cardiovasc Dis 52:512-524
57. Rossi GP, Seccia TM, and Nussdorfer GG. (2001). Reciprocal regulation of endothelin-1 and nitric oxide: Relevance in the physiology and pathology of the cardiovascular system. Int Rev Cytol 209:241-272 (Pubitemid 32911032)
58. Sartori C, Allemann Y, Trueb L, Delabays A, Nicod P, and Scherrer U. (1999). Augmented vasoreactivity in adult life associated with perinatal vascular insult. Lancet 353:2205-2207 (Pubitemid 29295254)
59. Sartori C, Lepori M, Busch T, et al. (1999). Exhaled nitric oxide does not provide a marker of vascular endothelial function in healthy humans. Am J Respir Crit Care Med 160:879-882 (Pubitemid 29442024)
60. Sartori C, Lepori M, and Scherrer U. (2005). Interaction between nitric oxide and the cholinergic and sympathetic nervous system in cardiovascular control in humans. Pharmacol Ther 106:209-220 (Pubitemid 40603865)
61. Sartori C, Trueb L, and Scherrer U. (1997). High-Altitude pulmonary edema. Mechanisms and management. Cardiologia 42:559-567
62. Sartori C, Vollenweider L, Löffler B-M, et al. (1999). Exaggerated endothelin release in high-Altitude pulmonary edema. Circulation 99:2665-2668 (Pubitemid 29237454)
63. Scherrer U, Allemann Y, Jayet PY, Rexhaj E, and Sartori C. (2010). High altitude, a natural research laboratory for the study of cardiovascular physiology and pathophysiology. Prog Cardiovasc Dis 52:451-455
64. Scherrer U, Rexhaj E, Jayet PY, Allemann Y, and Sartori C. (2010). New insights in the pathogenesis of high-Altitude pulmonary edema. Prog Cardiovasc Dis 52:485-492
65. Scherrer U, Rimoldi SF, Rexhaj E, et al. (2012). Systemic and pulmonary vascular dysfunction in children conceived by assisted reproductive technologies. Circulation 125:1890-1896
66. Scherrer U, Sartori C, Lepori M, et al. (1999). High-Altitude pulmonary edema: From exaggerated pulmonary hypertension to a defect in transepithelial sodium transport. Adv Exp Med Biol 474:93-107
67. Scherrer U, Turini P, Thalmann S, et al. (2006). Pulmonary hypertension in high-Altitude dwellers: Novel mechanisms, unsuspected predisposing factors. Adv Exp Med Biol 588:277-291
68. Scherrer U, Vollenweider L, Delabays A, et al. (1996). Inhaled nitric oxide for high-Altitude pulmonary edema. N Eng J Med 334:624-629 (Pubitemid 26072119)
69. Scherrer U, Vollenweider P, Randin D, Jéquier E, Nicod P, and Tappy L. (1993). Suppression of insulin induced sympathetic activation and vasodilation by dexamethasone in humans. Circulation 88:388-394 (Pubitemid 23228037)
70. Settergren G, Angdin M, Astudillo R, et al. (1998). Decreased pulmonary vascular resistance during nasal breathing: Modulation by endogenous nitric oxide from the paranasal sinuses. Acta Physiol Scand 163:235-239 (Pubitemid 28335644)
71. Smith TG, Talbot NP, Privat C, et al. (2009). Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: Two randomized controlled trials. JAMA 302:1444-1450
72. Steegers EA, von Dadelszen P, Duvekot JJ, and Pijnenborg R. (2010). Pre-eclampsia. Lancet 376:631-644
73. Stuber T, Sartori C, Salmon CS, et al. (2008). Respiratory nitric oxide and pulmonary artery pressure in children of Aymara and European ancestry at high altitude. Chest 134:996-1000
74. Stuber T, Sartori C, Schwab M, et al. (2020). Exaggerated pulmonary hypertension during mild exercise in chronic mountain sickness. Chest 137:388-392
75. Thalmann S, Allemann Y, Jayet PY, et al. (2005). Oxidative stress mediated chronic pulmonary hypertension in re-entry pulmonary edema-prone high altitude dwellers. FASEB J 19:A1333
76. Wagner PD, Sutton JR, Reeves JT, Cymerman A, Groves BM, and Malconian MK. (1987). Operation Everest II: Pulmonary gas exchange during a simulated ascent of Mt. Everest. J Appl Physiol 63:2348-2359 (Pubitemid 18024857)
77. Ward MP, Milledge JS, and West JB. (1989). High Altitude Medicine and Physiology. Philadelphia: University of Pennsylvania Press